Am J Psychiatry. 2014 Feb;171(2):178-86. doi: 10.1176/appi.ajp.2013.13020225.
At least 50% of individuals with bipolar disorder have a lifetime anxiety disorder. Individuals with both bipolar disorder and a co-occurring anxiety disorder experience longer illness duration, greater illness severity, and poorer treatment response. The study explored whether comorbid lifetime anxiety in bipolar patients moderates psychotherapy treatment outcome.
In the Systematic Treatment Enhancement Program randomized controlled trial of psychotherapy for bipolar depression, participants received up to 30 sessions of intensive psychotherapy (family-focused therapy, interpersonal and social rhythm therapy, or cognitive-behavioral therapy) or collaborative care, a three-session comparison treatment, plus pharmacotherapy. Using the number needed to treat, we computed effect sizes to analyze the relationship between lifetime anxiety disorders and rates of recovery across treatment groups after 1 year.
A total of 269 patients (113 women) with a comorbid lifetime anxiety disorder (N=177) or without a comorbid lifetime anxiety disorder (N=92) were included in the analysis. Participants with a lifetime anxiety disorder were more likely to recover with psychotherapy than with collaborative care (66% compared with 49% recovered over 1 year; number needed to treat=5.88, small to medium effect). For patients without a lifetime anxiety disorder, there was no difference between rates of recovery in psychotherapy compared with collaborative care (64% compared with 62% recovered; number needed to treat=50, small effect). Participants with one lifetime anxiety disorder were likely to benefit from intensive psychotherapy compared with collaborative care (84% compared with 53% recovered; number needed to treat=3.22, medium to large effect), whereas patients with multiple anxiety disorders exhibited no difference in response to the two treatments (54% compared with 46% recovered; number needed to treat=12.5, small effect).
Depressed patients with bipolar disorder and comorbid anxiety may be in particular need of additional psychotherapy for treating acute depression. These results need to be replicated in studies that stratify bipolar patients to treatments based on their anxiety comorbidity status.
至少有 50%的双相情感障碍患者有终生焦虑障碍。患有双相情感障碍和共病焦虑症的个体经历更长的疾病持续时间、更严重的疾病严重程度和更差的治疗反应。本研究探讨了双相情感障碍患者共病终生焦虑是否会影响心理治疗的治疗效果。
在双相情感障碍抑郁的系统性治疗增强计划随机对照试验中,参与者接受了多达 30 节强化心理治疗(家庭为基础的治疗、人际和社会节律治疗或认知行为治疗)或合作护理,即三次比较治疗,加上药物治疗。使用需要治疗的人数,我们计算了效应大小,以分析在 1 年后,治疗组中终生焦虑障碍与恢复率之间的关系。
共有 269 名(113 名女性)患有共病终生焦虑障碍(N=177)或无共病终生焦虑障碍(N=92)的患者纳入分析。有终生焦虑障碍的患者通过心理治疗比合作护理更有可能康复(66%与 1 年内康复的 49%相比;需要治疗的人数=5.88,小到中效)。对于没有终生焦虑障碍的患者,心理治疗与合作护理的康复率无差异(64%与 62%在 1 年内康复;需要治疗的人数=50,小效应)。患有一种终生焦虑障碍的患者可能会从强化心理治疗中受益,而不是合作护理(84%与 53%康复;需要治疗的人数=3.22,中到大量效应),而患有多种焦虑障碍的患者对两种治疗方法的反应没有差异(54%与 46%康复;需要治疗的人数=12.5,小效应)。
患有双相情感障碍和共病焦虑的抑郁患者可能特别需要额外的心理治疗来治疗急性抑郁。这些结果需要在基于焦虑共病状态对双相情感障碍患者进行分层治疗的研究中得到复制。